[E-Daily Reporter Hyera Lee ] #ROKIT HEALTHCARE Inc., an AI-based organ regeneration platform, surged 16% early in the session, continuing its upward trend for the fourth consecutive day. According to MP Doctor on the 15th, as of 9:27 a.m. that day, ROKIT HEALTHCARE Inc. was trading at 53,000 won, up 16.81% from the previous trading day. The stock price surge is driven by the start of human clinical trials for kidney regeneration surgery. ROKIT HEALTHCARE Inc. announced on the 13th that it had obtained final approval for the related surgery from the Institutional Review Board (IRB) for Advanced Regenerative Medicine at Asan Medical Center in Seoul. Having cleared all regulatory hurdles following approval of its research plan by the Ministry of Health and Welfare last May, the company is expected to begin surgeries on 10 patients with chronic kidney disease starting this month. ROKIT HEALTHCARE Inc. official stated, “The core technology applied in these surgeries has already been patented in the United States, Japan, and South Korea,” adding, “We plan to pursue rapid approval for advanced regenerative treatments as soon as this clinical trial is completed.”
LG Display posted an operating loss of 107.7 billion won in the second quarter of this year. The company recorded a loss in the second quarter due to one-time costs of approximately 240 billion won re…
Competition in the e-commerce industry is expanding beyond “speed” to encompass the “shopping experience” as a whole. Fast delivery has already become a basic competitive advantage, and the key to suc…
WebCash ( WebCash Corporation(053580)), a B2B financial Agent AI company, will participate in INDUSTRIALBANKOFKOREA’s next-generation digital banking construction project.WebCash Corporation announced…
